^
Association details:
| Biomarker: | TMB-H + PD-L1 expression |
|---|---|
| Cancer: | Penile Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
Published date:
04/21/2020
Excerpt:
The patient was then administered with toripalimab (240 mg iv d2, 21 d/cycle), an immune check point inhibitor (ICI), since February 27, 2019 on top of the chemotherapy regimen. Partial response was soon observed on April 15, 2019...first case in China describing an advanced PSCC patient with positive PD-L1 and high TMB who obtained remarkable response to immunotherapy.
DOI:
10.2147/OTT.S231258
